Rigel Pharmaceuticals, Inc. (RIGL) Reports In-Line Q2 EPS
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $47.55 -2.3%
EPS Growth %: -34.9%
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -34.9%
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) reported Q2 EPS of ($0.35), in-line with the analyst estimate of ($0.35). Revenue for the quarter came in at $1.15 million versus the consensus estimate of $550 thousand.
For earnings history and earnings-related data on Rigel Pharmaceuticals, Inc. (RIGL) click here.
For earnings history and earnings-related data on Rigel Pharmaceuticals, Inc. (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Activist investor presses Xerox to review financial services arm - Bloomberg
- Avianca secures first of its kind financing from the Brazilian Agency for the Management of Guarantee Funds and Guarantees (ABGF) for Maintenance, Repair and Overhaul (MRO) services at GE Aerospace's
- UBS upgrades Lockheed Martin to Buy, sees 26% upside on missile growth
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
